Nandrolone and Tamoxifen Interaction: Avoid | Peptide Database

Winlevi (clascoterone cream 1%) is FDA-approved for the topical treatment of acne vulgaris in patients 12 years and older. Phase 3 trials demonstrated statistically significant reductions in inflammatory and non-inflammatory lesion counts compared to vehicle, with an Investigator Global Assessment success rate significantly higher than placebo. Particularly relevant for women with androgen-driven acne who cannot tolerate or prefer to avoid systemic anti-androgens like spironolactone. Provides targeted anti-androgen activity at the sebaceous gland without the systemic effects, menstrual irregularities, or contraindication in pregnancy associated with oral anti-androgens. Breezula (clascoterone solution 7.5%) has completed Phase 3 clinical trials for androgenetic alopecia in men. Trial results showed improvements in target area hair count compared to vehicle. Regulatory submission is pending. The topical anti-androgen approach offers a potential alternative to systemic 5-alpha reductase inhibitors for men concerned about systemic side effects. The favorable safety profile and lack of systemic anti-androgenic effects make clascoterone a candidate for female androgenetic alopecia, where systemic anti-androgens carry teratogenic risks. Clinical data in women for this indication is still being developed.

Proviron is one of the most reliable compounds for improving sexual desire and drive. Its DHT activity directly stimulates libido pathways, while its SHBG-binding effect increases free testosterone availability. Effects are often noticeable within the first week of use. By increasing free testosterone and DHT activity, Proviron can improve erectile firmness and frequency. Particularly effective in men whose erectile issues are related to low free testosterone or elevated SHBG. At doses of 25-50 mg/day, Proviron has been used clinically to improve sperm count and motility in oligospermic men. At these low doses, HPT axis suppression is minimal. Higher doses may suppress spermatogenesis. Proviron is widely reported to produce a noticeable improvement in mood, confidence, and overall psychological well-being. This is attributed to increased free testosterone and direct androgenic activity in the central nervous system. Many users describe a calm, confident, and motivated mindset. In men with documented androgen deficiency, Proviron has been used to alleviate depressive symptoms, fatigue, and loss of motivation. Not a replacement for standard psychiatric treatment but can complement hormonal optimization. Proviron reduces water retention and gives a visibly harder, more defined appearance. It does not significantly build muscle mass on its own due to rapid inactivation in muscle tissue, but it enhances the aesthetic quality of existing musculature. By binding SHBG and freeing bound testosterone, Proviron effectively increases the anabolic signal from a given testosterone dose. This makes it a potent adjunct to any testosterone-based protocol for improving body composition outcomes. Proviron has one of the highest binding affinities for SHBG of any androgen. This displaces testosterone from SHBG, increasing free testosterone without increasing total testosterone dose. Particularly useful in men with elevated SHBG who present with low free testosterone despite adequate total testosterone levels. Proviron provides a mild anti-estrogenic effect through aromatase competition, which can reduce or eliminate the need for a dedicated aromatase inhibitor on moderate testosterone doses. It is not a replacement for an AI in heavily aromatizing protocols but can meaningfully reduce estrogen-related side effects in standard TRT.